Meeting objectives and introduction
David Maloney & Frederick Locke

Welcome to the solid tumors day
Kedar Kirtane & Sarah Nikiforow

Keynote talk 1
How solid CAR-T targeting has evolved: Prasad Adusumilli

Session 1: CARs targeting cell surface proteins (part I)
Chairs: Susanne Baumeister & Kedar Kirtane

• DLL3-CAR-T for SCLC: Adam Schoenfeld
• GCC19 CAR-T therapy for refractory colorectal cancer: Overcoming challenges in expansion and persistence: Benjamin Schlechter
• Updates on logic-gated CAR T-cell therapies in pancreatic cancer: Joel Randolph Hecht
• An update on CAR T-cell therapy for breast and ovarian cancer: A long and winding road: Jennifer Specht

Panel discussion

Session 2: CARs targeting cell surface proteins (part II)
Chairs: Joel Randolph Hecht & Jennifer Specht

• CLDN6-targeted therapy with CAR-T cells +/- CARVac in relapsed germ cell tumors: Winfried Alsdorf
• hALK.CAR T cells for relapsed/refractory neuroblastoma: Susanne Baumeister
• Cell therapy advances in ovarian cancer: What we know and where we’re headed: Monica Avila

Panel discussion

Break

Session 3: T-cell engagers and TCRs
Chairs: Sarah Nikiforow & Benjamin Creelan

• Afami-Cel in Metastatic Synovial Sarcoma: The 1^st genetically engineered TCR therapy approved for a solid tumor: Mihaela Druta
• Immunologic targeting of undruggable TP53 hotspot mutations through T cell receptor gene therapy: Mike Gormally
• Targeting PRAME with TCR T cells first in melanoma then beyond: Jason Luke

Panel discussion

Lunch

Session 4: TILs across solid tumors
Chairs: Allison Betof Warner & Claire Roddie

• Promising T cell targets in lung cancers: Trial updates: Benjamin Creelan
• TIL therapy for GU malignancies: Michael Poch
• Optimizing TIL therapy for melanoma & beyond: Allison Betof Warner

Panel discussion

Session 5: Novel technologies in solid tumors
Chairs: Sarah Nikiforow & Kedar Kirtane 

• Genome-edited anti-GPC3 CAR for hepatoma: Marco Davila
• CAR-M: Engineering myeloid cells for solid tumor immunotherapy: Saar Gill
• Cell and gene therapy: Current status and future directions – An industry perspective: Will Go
• Advancing T cell therapies for solid cancers: Saul Priceman

Panel discussion

Break

Session 6: T-cell engagers and CARs in CLL
Chairs: David Maloney & Saar Gill

• Optimizing liso-cel in CLL: Sequencing and combination strategies: Mazyar Shadman
• Why bispecific antibodies may be the path forward in CLL: Alexey Danilov

Panel discussion

Session 7: CAR-T in ALL
Chairs: Claire Roddie & Saar Gill

• Obecabtagene autoleucel: What have we learned from the FELIX study?: Claire Roddie
• CAR T-cell therapy in B-cell ALL: Bijal Shah
• CD19/CD22 CAR-T: Noelle Frey
• SCRI‐CAR19 with CD19 T‐APC to prolong CAR T cell persistence: Rebecca Gardner
• Improving clinical activity of CD5 CART in T-ALL: Maksim Mamonkin

Panel discussion

Day 1 conclusions

Welcome reception

Welcome to Day 2
Sarah Nikiforow & Yi Lin

Keynote talk 2
Frontiers in CAR T-cell therapy for autoimmune diseases: David Porter

Session 8: CAR therapy for autoimmune diseases
Chairs: David Porter & David Miklos

• Early experience with the in vivo expanding anti-CD19 CAR-T, BMS-986353 for autoimmunity: Lazaros Lekakis
• CD19 CAR NK-cell therapy for B-cell mediated autoimmune disease: David Shook
• CAR T for dermatomyositis: Saurabh Dahiya
• Antigen-specific treatment of myasthenia: Development of rat chimeric autoantibody receptor
  (CAAR) T cells to treat experimental autoimmune MuSK myasthenia: David Richman
• State of the art with CAR therapy in MG: Ali Habib

Panel discussion

Session 9: How do we integrate autoimmune diseases into cell therapy centres?
Chairs: David Maloney & Sarah Nikiforow

Discussants: Frederick Locke, David Porter, Claire Roddie

Break

Session 10: Translational studies with T-cell engagers and CARs   
Chairs: Yi Lin & Saar Gill

• Genomic determinants of resistance to anti BCMA and GPRC5D therapies: Francesco Maura
• Metabolic fitness in CAR-T cells from earlier in the treatment course: Ciara Freeman
• Insights into microbiome and microbial metabolites to augment CAR-T therapy: Maik Luu

Panel discussion

Keynote talk 3
Accelerating CAR T-cell therapeutics with small molecules and CRISPR2.0 gene-edits: Michael Hudecek

Lunch

Session 11: T-cell engagers for multiple myeloma
Chairs: Saad Usmani & Ciara Freeman 

• Cevostamab: What, how and when?: Rakesh Popat
• Teclistamab – the past was good, the future could be great!!: Tom Martin
• The Balancing Act of Talquetamab: Nisha Joseph
• Multi-antigen targeting with trispecific antibodies in myeloma: JNJ-796353222: Sham Mailankody

Panel discussion

Session 12: CAR therapy for multiple myeloma
Chairs: Adam Sperling & Krina Patel

• CAR-T cells in multiple myeloma: The evolving use of cilta-cel and ide-cel: Adam Sperling
• Phase I / II summary of anito-cel for relapsed/refractory MM: Matthew Frigault
• Arlocabtagene autoleucel in relapsed refractory multiple myeloma: Susan Bal
• BCMA CAR-T clash of the Titans: Idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: Doris Hansen

Panel discussion

Break

Session 13: CAR therapy should come before T-cell engagers in multiple myeloma treatment sequencing
Chairs: Yi Lin & Doris Hansen

• For: Krina Patel
• Against: Sham Mailankody

Panel discussion

Session 14: Different approaches to CAR production in lymphoma
Chairs: David Maloney & Caron Jacobson

• Rapcabtagene autoleucel for B-cell lymphomas and the potential role of CAR-T rapid manufacturing: Julio Chavez
• Point-of-care manufacturing with Canadian-made CD19 CART, CLIC-1901: Natasha Kekre
• ATALANTA-1: A Phase 1/2 trial of GLPG5101, a fresh, stem-like, early memory CD19 CAR T-cell therapy with a 7-day vein-to-vein time, for the treatment of relapsed/refractory non-Hodgkin lymphoma: Caron Jacobson
• Interim result multicenter Phase II trial of zamtocabtagene autoleucel, an non-cryopreserved anti-CD20/anti-CD19 CAR T cell product for relapsed, refractory DLBCL: Nirav Shah

Panel discussion

Day 2 conclusions

 Offsite Attendee Dinner

Welcome to Day 3
Caron Jacobson & Frederick Locke

Session 15: Long-term follow-up and outcomes with CARs
Chairs: David Miklos & Elizabeth Budde

• Long-term complications after CAR T-cell therapy: Michael Jain
• Beyond CRS and ICANS: Non-relapse mortality after CAR T-cell therapy: Kai Rajeski
• Catch me if you can: Lymphoma resistance to CAR T immunotherapy: Marco Ruella
• Enhancing CAR T-cell activity and persistence with CAR-enhancer therapeutics: Mohamad Rashidian

Panel discussion

Session 16: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & Marion Subklewe

• Back to the bench: Rethinking CAR T for AML: Marion Subklewe
• Allogeneic, off-the-shelf, CAR T cells for AML: CB-012: Jae Park
• Treatment of JMML and CMML with CLL-1 CAR-T cells +/- trametinib: Elliot Stieglitz
• Immunotherapy in CALR-mutated myeloproliferative neoplasms: Approach with caution: Andrew Kuykendall

Panel discussion

Break

Session 17: What are the current challenges with CAR T in lymphoma and how can we address them?
Chairs: Caron Jacobson & David Miklos

• Barriers: Why is CAR T-cell therapy not reaching its potential in heme malignancies?: Jason Westin
• Sequencing novel treatment options in lymphoma: Gloria Iacoboni
• Clinical Development in B cell Malignancies: Have we reached the finish or hit a wall?: Frederick Locke

Panel discussion

Keynote talk 4
Building a fast-paced outpatient IEC program: Elizabeth Budde

Working lunch

Session 18: T-cell engagers and CARs in lymphomas (part I)
Chairs: Tycel Phillips & Jennifer Crombie                                                                                                                                                     

• Update on CB-010/allogeneic anti-CD19 CAR-T cell therapy: Mehdi Hamadani
• Fixed-duration treatment with epcoritamab: Alexey Danilov
• Bispecifics in lymphoma: Moving beyond CD20 targeting: Krish Patel

Panel discussion

Session 19: T-cell engagers and CARs in lymphomas (part II)
Chairs: Jason Westin & Gloria Iacoboni

• Frontline & second-line DLBCL treatments – where are we in 2025?: Matt Lunning
• Bispecific combinations in relapsed/refractory DLBCL: Jennifer Crombie
• “Who’s on first”….Sequencing bispecifics with CAR-T in indolent lymphoma: Tycel Philips

Panel discussion

Keynote talk 5
Moving bispecifics and CAR T-cell therapies into the community setting: Tara Graff

Session 20: How to get CAR T-cell therapy into the community setting?
Chairs: Elizabeth Budde & Krish Patel  

Discussants: Tara Graff, Caron Jacobson, Frederick Locke

Meeting conclusions